In this study, we investigated how replication is perturbed in BRCA1-deficient cancer cells treated with multiple doses of cisplatin, a crosslinking agent frequently used to treat ovarian cancers (Helm and States, 2009). This evidence concerns the gene BRCA1 and ovarian cancer.